Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8980 results

  1. Digital technologies delivering CBT for insomnia in adults

    In development Reference number: GID-HTE10068 Expected publication date:  06 January 2027

    Health technology evaluations
    In development

  2. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  3. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  4. Deuruxolitinib for treating severe alopecia areata [ID6597]

    In development Reference number: GID-TA11804 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  5. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  6. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  7. Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]

    Awaiting development Reference number: GID-TA11811 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  9. Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

    In development Reference number: GID-TA11733 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  10. Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

    In development Reference number: GID-TA11341 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  11. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  12. Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]

    In development Reference number: GID-TA11693 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  14. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]

    In development Reference number: GID-TA11416 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  15. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over [ID6448]

    In development Reference number: GID-TA11564 Expected publication date: TBC

    Technology appraisal guidance
    In development